Valsartan/Hydrochlorothiazide Dispersible Tablets Recall Complete
Published Time:
2018-10-23
On September 20, 2018, a joint working group from the Jiangsu Provincial Food and Drug Administration, Nantong Municipal Food and Drug Administration, and Haimen Municipal Market Supervision Administration visited our company to conduct an on-site inspection of the recall work and to summarize and evaluate the recall situation.
Valsartan Hydrochlorothiazide Dispersible Tablets Recall Completed
On September 20, 2018, a joint working group from the Jiangsu Provincial Food and Drug Administration, Nantong Municipal Food and Drug Administration, and Haimen Municipal Market Supervision and Administration Bureau visited our company to conduct an on-site inspection of the recall work and conduct a summary assessment of the recall situation.
Our company's recall work has been underway for over two months, with nearly one million boxes of Valsartan Hydrochlorothiazide Dispersible Tablets recalled.
The joint inspection team's overall assessment is that the company attaches great importance to drug quality, has a relatively positive attitude towards the recall, and the recall work is relatively meticulous. After verifying the drug batch production records, drug sales records, summary table of drugs to be recalled, summary table of recalled drugs, physical inventory in the recall warehouse, and the trend analysis chart of drug recall in the terminal market, the assessment team believes that the drugs to be recalled have been basically recalled, and the drug recall procedure can be closed in principle.
As of September 30, 2018, the company's recall hotline has received over 1,300 calls, and no adverse reaction reports related to this recall have been received.
Based on the above, the voluntary recall of our company's Valsartan Hydrochlorothiazide Dispersible Tablets has been completed. If patients still need to return or exchange goods later, they can continue to do so through the channels announced by the company, and our company will continue to provide support in this regard.
Jiangsu Wangao Pharmaceutical Co., Ltd.
September 30, 2018
Previous Page
Previous Page:
Recommended News
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
Whatsapp Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.